Insider Trading disclosures for Cytokinetics Inc

The latest disclosure was made by Robert I. Blum in Cytokinetics Inc where a trade of 25,000 Common Stock done at an average price of $44.7 was reported to US exchanges on March 17, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Show

Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
Robert I. Blum	Director, President & CEO	Sale of securities on an exchange or to another person at price $ 44.65 per share.	17 Mar 2025	25,000	339,181 (0%)	0%	44.7	1,116,250	Common Stock
Robert I. Blum	Director, President & CEO	Sale of securities on an exchange or to another person at price $ 44.38 per share.	17 Mar 2025	12,648	326,533 (0%)	0%	44.4	561,318	Common Stock
Fady Ibraham Malik	EVP Research & Development	Sale of securities on an exchange or to another person at price $ 44.38 per share.	17 Mar 2025	4,389	101,005 (0%)	0%	44.4	194,784	Common Stock
Andrew M. Callos	EVP, Chief Commercial Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.26 per share.	17 Mar 2025	20,900	58,563 (0%)	0%	23.3	486,134	Common Stock
Andrew M. Callos	EVP, Chief Commercial Officer	Sale of securities on an exchange or to another person at price $ 44.38 per share.	17 Mar 2025	2,775	34,888 (0%)	0%	44.4	123,155	Common Stock
Andrew M. Callos	EVP, Chief Commercial Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	17 Mar 2025	20,900	129,000	-		-	Non-Qualified Stock Option (Right to Buy)
Andrew M. Callos	EVP, Chief Commercial Officer	Sale of securities on an exchange or to another person at price $ 45.14 per share.	17 Mar 2025	20,900	37,663 (0%)	0%	45.1	943,426	Common Stock
Andrew M. Callos	EVP, Chief Commercial Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	14 Mar 2025	100	149,900	-		-	Non-Qualified Stock Option (Right to Buy)
Andrew M. Callos	EVP, Chief Commercial Officer	Sale of securities on an exchange or to another person at price $ 45.00 per share.	14 Mar 2025	100	37,663 (0%)	0%	45	4,500	Common Stock
Andrew M. Callos	EVP, Chief Commercial Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.26 per share.	14 Mar 2025	100	37,763 (0%)	0%	23.3	2,326	Common Stock
Robert I. Blum	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	14 Mar 2025	116,096	480,277 (0%)	0%		0	Common Stock
Robert I. Blum	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	14 Mar 2025	176,547	176,547	-		-	Non-Qualified Stock Option (Right to Buy)
Robert I. Blum	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	14 Mar 2025	2,254	2,254	-		-	Incentive Stock Option (Right to Buy)
Fady Ibraham Malik	EVP Research & Development	Grant, award, or other acquisition of securities at price $ 0.00 per share.	14 Mar 2025	2,293	2,293	-		-	Incentive Stock Option (Right to Buy)
Fady Ibraham Malik	EVP Research & Development	Grant, award, or other acquisition of securities at price $ 0.00 per share.	14 Mar 2025	58,465	58,465	-		-	Non-Qualified Stock Option (Right to Buy)
Fady Ibraham Malik	EVP Research & Development	Grant, award, or other acquisition of securities at price $ 0.00 per share.	14 Mar 2025	39,450	144,844 (0%)	0%		0	Common Stock
Andrew M. Callos	EVP, Chief Commercial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	14 Mar 2025	47,593	47,593	-		-	Non-Qualified Stock Option (Right to Buy)
Andrew M. Callos	EVP, Chief Commercial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	14 Mar 2025	2,749	2,749	-		-	Incentive Stock Option (Right to Buy)
Andrew M. Callos	EVP, Chief Commercial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	14 Mar 2025	32,687	70,350 (0%)	0%		0	Common Stock
Andrew M. Callos	EVP, Chief Commercial Officer	Sale of securities on an exchange or to another person at price $ 43.62 per share.	13 Mar 2025	26,771	37,663 (0%)	0%	43.6	1,167,751	Common Stock
Robert I. Blum	Director, President & CEO	Sale of securities on an exchange or to another person at price $ 43.44 per share.	06 Mar 2025	16,970	364,181 (0%)	0%	43.4	737,177	Common Stock
Fady Ibraham Malik	EVP Research & Development	Sale of securities on an exchange or to another person at price $ 43.27 per share.	06 Mar 2025	8,228	105,394 (0%)	0%	43.3	356,026	Common Stock
Andrew M. Callos	EVP, Chief Commercial Officer	Sale of securities on an exchange or to another person at price $ 43.27 per share.	06 Mar 2025	3,341	64,434 (0%)	0%	43.3	144,565	Common Stock
Robert I. Blum	Director, President & CEO	Sale of securities on an exchange or to another person at price $ 43.23 per share.	05 Mar 2025	25,000	381,151 (0%)	0%	43.2	1,080,750	Common Stock
Fady Ibraham Malik	EVP Research & Development	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	04 Mar 2025	2,000	31,105	-		-	Non-Qualified Stock Option (Right to Buy)
Fady Ibraham Malik	EVP Research & Development	Sale of securities on an exchange or to another person at price $ 42.50 per share.	04 Mar 2025	2,000	116,071 (0%)	0%	42.5	85,000	Common Stock
Fady Ibraham Malik	EVP Research & Development	Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share.	04 Mar 2025	2,000	118,071 (0%)	0%	10.6	21,200	Common Stock
Robert A. Harrington	Director	Sale of securities on an exchange or to another person at price $ 42.50 per share.	04 Mar 2025	900	15,108 (0%)	0%	42.5	38,250	Common Stock
Robert I. Blum	Director, President & CEO	Sale of securities on an exchange or to another person at price $ 42.88 per share.	03 Mar 2025	8,743	406,151 (0%)	0%	42.9	374,900	Common Stock
Fady Ibraham Malik	EVP Research & Development	Sale of securities on an exchange or to another person at price $ 42.88 per share.	03 Mar 2025	2,449	113,622 (0%)	0%	42.9	105,013	Common Stock
Andrew M. Callos	EVP, Chief Commercial Officer	Sale of securities on an exchange or to another person at price $ 42.88 per share.	03 Mar 2025	1,114	67,775 (0%)	0%	42.9	47,768	Common Stock
Fady Ibraham Malik	EVP Research & Development	Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share.	18 Feb 2025	2,000	118,071 (0%)	0%	10.6	21,200	Common Stock
Fady Ibraham Malik	EVP Research & Development	Sale of securities on an exchange or to another person at price $ 45.98 per share.	18 Feb 2025	2,000	116,071 (0%)	0%	46.0	91,960	Common Stock
Fady Ibraham Malik	EVP Research & Development	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	18 Feb 2025	2,000	33,105	-		-	Non-Qualified Stock Option (Right to Buy)
Robert E. Landry	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	10 Feb 2025	25,538	25,538	-		-	Non-Qualified Stock Option (Right to Buy)
Fady Ibraham Malik	EVP Research & Development	Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share.	04 Feb 2025	2,000	118,071 (0%)	0%	10.6	21,200	Common Stock
Fady Ibraham Malik	EVP Research & Development	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	04 Feb 2025	2,000	35,105	-		-	Non-Qualified Stock Option (Right to Buy)
Fady Ibraham Malik	EVP Research & Development	Sale of securities on an exchange or to another person at price $ 48.06 per share.	04 Feb 2025	2,000	116,071 (0%)	0%	48.1	96,120	Common Stock
Fady Ibraham Malik	EVP Research & Development	Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.60 per share.	21 Jan 2025	2,000	118,071 (0%)	0%	10.6	21,200	Common Stock
Fady Ibraham Malik	EVP Research & Development	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	21 Jan 2025	2,000	37,105	-		-	Non-Qualified Stock Option (Right to Buy)
Fady Ibraham Malik	EVP Research & Development	Sale of securities on an exchange or to another person at price $ 45.92 per share.	21 Jan 2025	2,000	116,071 (0%)	0%	45.9	91,840	Common Stock
John T. Henderson	Director	Grant, award, or other acquisition of securities at price $ 48.93 per share.	02 Jan 2025	434	48,987 (0%)	0%	48.9	21,236	Common Stock
Nancy J. Wysenski	Director	Grant, award, or other acquisition of securities at price $ 48.93 per share.	02 Jan 2025	127	23,115 (0%)	0%	48.9	6,214	Common Stock
Wendell D. Wierenga	Director	Grant, award, or other acquisition of securities at price $ 48.93 per share.	02 Jan 2025	127	24,686 (0%)	0%	48.9	6,214	Common Stock
Edward M. Kaye	Director	Grant, award, or other acquisition of securities at price $ 48.93 per share.	02 Jan 2025	255	25,637 (0%)	0%	48.9	12,477	Common Stock
Robert A. Harrington	Director	Grant, award, or other acquisition of securities at price $ 48.93 per share.	02 Jan 2025	255	16,008 (0%)	0%	48.9	12,477	Common Stock
Wendell D. Wierenga	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.37 per share.	16 Dec 2024	742	25,301 (0%)	0%	7.4	5,469	Common Stock
Wendell D. Wierenga	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	16 Dec 2024	742	0	-		-	Non-Qualified Stock Option (Right to Buy)
Wendell D. Wierenga	Director	Sale of securities on an exchange or to another person at price $ 48.61 per share.	16 Dec 2024	742	24,559 (0%)	0%	48.6	36,069	Common Stock
John T. Henderson	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.37 per share.	11 Dec 2024	1,780	40,241 (0%)	0%	7.4	13,119	Common Stock

Showing 1 to 50 of 500 entries

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades disclosures

42.83% Fall from 52W High

Insider Trading disclosures for Cytokinetics Inc

The latest disclosure was made by Robert I. Blum in Cytokinetics Inc where a trade of 25,000 Common Stock done at an average price of $44.7 was reported to US exchanges on March 17, 2025.

Screeners based on Insider Trading and SAST parameters